About a third of our subjects had elevated CRP and possible motivational anhedonia suggesting that infliximab may be a viable experimental therapy for a “neuroinflammatory” phenotype of ME/CFS and GWI. Here, CRP is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.